Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Article
in En
| MEDLINE
| ID: mdl-29482983
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Aromatase Inhibitors
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2018
Type:
Article
Affiliation country:
Italy